Secukinumab in moderate to severe hidradenitis suppurativa: Week 16 results of hurley stage II and III from the sunshine and sunrise phase 3 randomized trials

被引：0

作者：

Kimball, Alexa B. ^{[1
,2
]}

Alavi, Afsaneh ^{[3
,4
]}

Jemec, Gregor B. E. ^{[3
,5
]}

Zouboulis, Christos C. ^{[3
,6
,7
,8
,9
,10
]}

Wozniak, Magdalena B. ^{[11
]}

Uhlmann, Lorenz ^{[12
]}

Llobet-Martinez, Angela ^{[12
]}

Ravichandran, Shoba ^{[13
]}

Marzano, Angelo V. ^{[3
,14
,15
]}

Reguiai, Ziad ^{[3
,16
]}

机构：

[1] Harvard Med Sch, Boston, MA USA

[2] Beth Israel Deaconess Med Ctr, Dermatol, Boston, MA USA

[3] European Hidradenitis Suppurat Fdn eV, Dessau, Germany

[4] Mayo Clin, Dermatol, Rochester, MN USA

[5] Zealand Univ Hosp Roskilde, Dermatol, Roskilde, Denmark

[6] Brandenburg Med Sch Theodor Fontane, Dessau, Germany

[7] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Dermatol, Dessau, Germany

[8] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Venereol, Dessau, Germany

[9] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Allergol, Dessau, Germany

[10] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Immunol, Dessau, Germany

[11] Novartis Ireland Ltd, Dublin, Ireland

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[15] Univ Milan, Dermatol Pathophysiol & Transplantat, Milan, Italy

[16] Polyclin Courlancy Bezannes, Dermatol, Reims, France

来源：

EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：25 / 26

页数：2

共 50 条

[31] Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting
Ribero, S.
Ramondetta, A.
Fabbrocini, G.
Bettoli, V.
Potenza, C.
Chiricozzi, A.
Licciardello, M.
Marzano, A. V.
Bianchi, L.
Rozzo, G.
Fania, L.
Marasca, C.
Odorici, G.
Mambrin, A.
Moltrasio, C.
Caposiena Caro, R. D.
Skroza, N.
Quaglino, P.
Siliquini, N.
Dapavo, P.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (07) : E441 - E442
[32] Efficacy and safety results from the SHARPS study: Phase 4, randomized, controlled trial of adalimumab plus surgery in moderate-to-severe hidradenitis suppurativa
Bechara, Falk G.
Horvath, Barbara
Jemec, Gregor B. E.
Podda, Maurizio
Prens, Errol P.
Geng, Ziqian
Jean, Christine
Zouboulis, Christos C.
EXPERIMENTAL DERMATOLOGY, 2020, 29 : 37 - 37
[33] Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials
Wei, Xiaoling
Passera, Anna
Muscianisi, Elisa
Uhlmann, Lorenz
Chen, Li
Moreno, Santiago G.
Martin, Ruvie
Vandemeulebroecke, Marc
Keefe, Deborah
Ravichandran, Shoba
Wozniak, Magdalena B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (06) : 1285 - 1287
[34] Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies
Alavi, Afsaneh
Hamzavi, Iltefat
Brown, Kurt
Santos, Leandro L.
Zhu, Zhaoyin
Liu, Huiqing
Howell, Michael D.
Kirby, Joslyn S.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (05) : 803 - 813
[35] Safety and efficacy of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
Herra, L. Escudero
Kimball, A.
Zouboulis, C. C.
Armstrong, A. W.
Korman, N. J.
Crowley, J. J.
Lynde, C.
Belknap, K.
Gu, Y.
Williams, D. A.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 34
[36] Safety and efficacy of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
Kimball, Alexa
Zouboulis, Christos
Armstrong, April
Korman, Neil
Crowley, Jeffrey
Lynde, Charles
Belknap, Kimberly
Gu, Yihua
Williams, David
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB60 - AB60
[37] Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
Morita, Akimichi
Takahashi, Hidetoshi
Ozawa, Kentaro
Imafuku, Shinichi
Nakama, Takekuni
Takahashi, Kenzo
Matsuyama, Takashi
Okubo, Yukari
Kitamura, Susumu
Matsuda, Naoto
Zhao, Yiwei
Yokoyama, Masayuki
Hayashi, Nobukazu
Terui, Tadashi
JOURNAL OF DERMATOLOGY, 2019, 46 (09): : 745 - 751
[38] LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial
Schultheis, Michael
Staubach, Petra
Nikolakis, Georgios
Grabbe, Stephan
Ruckes, Christian
von Stebut, Esther
Kirschner, Uwe
Matusiak, Lukasz
Szepietowski, Jacek C.
DERMATOLOGY, 2022, 238 (03) : 476 - 486
[39] Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results
Morita, Akimichi
Takahashi, Hidetoshi
Ozawa, Kentaro
Imafuku, Shinichi
Takekuni, Nakama
Takahashi, Kenzo
Matsuyama, Takashi
Okubo, Yukari
Zhao, Yiwei
Kitamura, Susumu
Takei, Keiko
Yokoyama, Masayuki
Hayashi, Nobukazu
Terui, Tadashi
JOURNAL OF DERMATOLOGY, 2021, 48 (01): : 3 - 13
[40] Adalimumab Treatment in Women with Moderate to Severe Hidradenitis Suppurativa Using a Novel Endpoint, HiSCR (Hidradenitis Suppurativa Clinical Response): Analysis from the Placebo-Controlled Portion of a Phase II, Randomized, Double-Blind Study.
Gottlieb, Alice
Menter, Alan
Armstrong, April
Cui, Na
Yamaguchi, Yuji
REPRODUCTIVE SCIENCES, 2014, 21 (03) : 220A - 221A

← 1 2 3 4 5 →